Biohaven .(US:BHVN) Globenewswireยท2025-09-11 11:43Core Viewpoint - A class action lawsuit has been filed against Biohaven Ltd. for allegedly making materially false and misleading statements regarding its business and operations during the class period from March 24, 2023, to May 14, 2025 [2][4]. Group 1: Lawsuit Details - The lawsuit is on behalf of all individuals and entities who purchased or acquired Biohaven securities during the specified class period [2]. - Investors have until September 12, 2025, to apply to the Court to be appointed as lead plaintiff in the lawsuit [2]. Group 2: Allegations - The complaint alleges that Biohaven overstated the regulatory prospects of its treatment, troriluzole, for SCA, and the sufficiency of data submitted for its regulatory approval [4]. - It is also claimed that the efficacy and clinical prospects of BHV-7000 as a treatment for bipolar disorder were similarly overstated [4]. - The revelations of these overstated claims are likely to have a significant negative impact on Biohaven's business and financial condition [4]. Group 3: Contact Information - Investors who suffered losses or have questions regarding the lawsuit can contact Bragar Eagel & Squire, P.C. for more information [5][8].